Table 6. Ongoing clinical trials of first- and second-generation EGFR TKIs in combination with other targeted therapies in EGFR-mutant NSCLC patients.
| ClinicalTrials.gov identifier | Phase; population | Treatment | Status |
|---|---|---|---|
| NCT01487265 | Phase II; erlotinib-pretreated (sensitive) | Erlotinib + buparlisib (BKM120; selective PI3K inhibitor) | Ongoing, not recruiting |
| NCT01570296 | Phase Ib; EGFR TKI-pretreated; molecular alterations of PI3K pathway; EGFR overexpression | Gefitinib + buparlisib | Ongoing, not recruiting |
| NCT02424617 | Phase I/II; erlotinib-pretreated | Erlotinib + BGB324 (bemcentinib, R428; AXL inhibitor) | Recruiting |
| NCT03599518 | Phase I; EGFR TKI-pretreated | Gefitinib + DS-1205c (AXL inhibitor) | Not yet recruiting |
| NCT03333343 | Phase Ib; EGFR TKI-naive or not | Gefitinib + nazartinib (EGF816)1 | Recruiting |
| NCT03292133 | Phase II; EGFR TKI-naive | Gefitinib + nazartinib | Recruiting |
| NCT00600496 | Phase I; EGFR TKI-pretreated | Erlotinib + selumetinib (arm 3) | Ongoing, not recruiting |
| NCT03076164 | Phase I/II; erlotinib-pretreated | Erlotinib + trametinib | Recruiting |
| NCT01859026 | Phase I/Ib; EGFR TKI-naive or not | Erlotinib + MEK162 (binimetinib; selective MEK inhibitor) | Recruiting |
| NCT02468661 | Phase I/II; EGFR TKI-pretreated; c-MET amplified | Erlotinib + INC280 (capmatinib; c-MET inhibitor) vs. chemotherapy (phase II) | Recruiting |
| NCT01610336 | Phase IB/II; EGFR TKI-pretreated; c-MET amplified | Gefitinib + INC280 | Ongoing, not recruiting |
| NCT02374645 | Phase Ib; EGFR TKI-pretreated; c-MET amplified | Gefitinib + volitinib (c-MET inhibitor) | Ongoing, not recruiting |
| NCT01982955 | Phase Ib/II; EGFR TKI-pretreated; c-MET amplified and T790M negative | Gefitinib + tepotinib (c-MET inhibitor) | Ongoing, not recruiting |
| NCT03122717 | Phase I; EGFR TKI-naive | Gefitinib + osimertinib (combined or alternative) | Recruiting |
| NCT02535338 | Phase I/II; EGFR TKI-pretreated | Erlotinib + onalespib lactate2 | Ongoing, not recruiting |
| NCT02716311 | Phase II; EGFR TKI-naive | Afatinib + cetuximab | Recruiting |
| NCT03623750 | Phase I/II; EGFR TKI-naive; EPICAL study | Afatinib + EGF-PTI3 | Recruiting |
| NCT03054038 | Phase I; EGFR TKI-pretreated | Afatinib + necitumumab | Recruiting |
| NCT02438722 | Phase II/III; EGFR TKI-naive; S1403 | Afatinib + cetuximab vs. afatinib | Recruiting |
| NCT01999985 | Phase I; EGFR TKI-pretreated; objective response, or stable disease for at least 6 months | Afatinib + dasatinib | Ongoing, not recruiting |
1EGF816, irreversible, third-generation, mutant-selective EGFR, with activity against T790M; 2onalespib lactate, the lactate form of onalespib, a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90); 3EGF-PTI, EGF pathway targeting immunisation. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer.